Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedMar 06, 2026
DataAggregated Company Financials
Companies180
  • 7D-1.5%
  • 3M-1.1%
  • 1Y6.9%
  • YTD0.3%

Over the last 7 days, the Pharma industry has dropped 1.5%, and Cipla contributed the most with a 2.3% decline. In the past year, the industry has gained 6.9%. As for the next few years, earnings are expected to grow by 16% per annum.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 06 Mar 2026₹20.4t₹4.3t₹621.2b26x32.9x4.7x
Sun, 01 Feb 2026₹19.5t₹4.2t₹606.9b28.6x32.2x4.6x
Tue, 30 Dec 2025₹20.3t₹4.2t₹614.5b28.4x33x4.8x
Thu, 27 Nov 2025₹20.5t₹4.2t₹611.5b29.5x33.6x4.9x
Sat, 25 Oct 2025₹20.4t₹4.1t₹592.0b30.2x34.4x5x
Mon, 22 Sep 2025₹20.7t₹4.1t₹587.9b32x35.3x5.1x
Wed, 20 Aug 2025₹20.4t₹4.1t₹589.0b30.8x34.6x5x
Fri, 18 Jul 2025₹21.1t₹4.0t₹594.1b32.7x35.5x5.3x
Sun, 15 Jun 2025₹20.4t₹4.0t₹595.3b33.7x34.3x5.1x
Tue, 13 May 2025₹19.2t₹3.9t₹565.9b29.6x33.9x4.9x
Thu, 10 Apr 2025₹18.3t₹3.9t₹559.2b27.3x32.7x4.7x
Sat, 08 Mar 2025₹18.7t₹3.9t₹559.4b28.4x33.5x4.8x
Mon, 03 Feb 2025₹19.6t₹3.9t₹543.8b30.5x36.1x5.1x
Wed, 01 Jan 2025₹21.4t₹3.8t₹527.0b34.2x40.5x5.6x
Fri, 29 Nov 2024₹20.2t₹3.8t₹526.7b33.1x38.4x5.3x
Sun, 27 Oct 2024₹20.6t₹3.7t₹495.0b37x41.6x5.5x
Tue, 24 Sep 2024₹21.4t₹3.7t₹492.6b41.1x43.4x5.7x
Thu, 22 Aug 2024₹20.7t₹3.7t₹492.6b36.8x41.9x5.6x
Sat, 20 Jul 2024₹18.6t₹3.6t₹449.9b34.5x41.3x5.2x
Mon, 17 Jun 2024₹17.7t₹3.6t₹448.3b32.3x39.4x5x
Wed, 15 May 2024₹16.9t₹3.5t₹428.5b33.5x39.4x4.8x
Fri, 12 Apr 2024₹17.1t₹3.5t₹418.9b33.5x40.9x4.9x
Sun, 10 Mar 2024₹17.1t₹3.5t₹418.7b33.4x40.8x4.9x
Tue, 06 Feb 2024₹16.4t₹3.4t₹411.4b34.2x39.8x4.8x
Thu, 04 Jan 2024₹15.6t₹3.4t₹395.9b34.8x39.3x4.6x
Sat, 02 Dec 2023₹14.3t₹3.4t₹395.1b31.6x36.2x4.2x
Mon, 30 Oct 2023₹12.8t₹3.3t₹375.3b28.8x34.2x3.9x
Wed, 27 Sep 2023₹12.9t₹3.3t₹369.5b29.8x34.9x3.9x
Fri, 25 Aug 2023₹13.0t₹3.3t₹367.0b29.5x35.3x4x
Sun, 23 Jul 2023₹12.2t₹3.2t₹342.7b26.1x35.7x3.9x
Tue, 20 Jun 2023₹11.4t₹3.2t₹342.4b26.4x33.4x3.6x
Thu, 18 May 2023₹10.4t₹3.1t₹309.6b26.6x33.7x3.4x
Sat, 15 Apr 2023₹9.9t₹3.0t₹277.6b25.5x35.5x3.3x
Mon, 13 Mar 2023₹9.4t₹3.0t₹277.5b24.4x33.7x3.1x
Price to Earnings Ratio

33.7x


Total Market Cap: ₹9.4tTotal Earnings: ₹277.5bTotal Revenue: ₹3.0tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.6x202420252026
Current Industry PE
  • Investors are pessimistic on the Indian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 32.9x which is lower than its 3-year average PE of 36.6x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 13% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market-3.41%
Healthcare-1.82%
Pharma-1.51%
Pharma-1.51%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
500488 Abbott India₹27.60k4.8%
+₹26.8b		-11.0%PE38.5x
NATCOPHARM NATCO Pharma₹1.00k2.9%
+₹5.1b		21.6%PE11.5x
500257 Lupin₹2.33k0.4%
+₹4.2b		15.5%PE22.9x
ACUTAAS Acutaas Chemicals₹2.23k2.3%
+₹4.1b		81.5%PE63.8x
AUROPHARMA Aurobindo Pharma₹1.23k0.4%
+₹2.8b		10.0%PE20.4x

Latest News

AETHER
₹967.30
Aether Industries
7D
0.6%
1Y
6.8%

AETHER: Upcoming Board Meeting Will Support Constructive Long Term Outlook

Analysts have maintained their price target for Aether Industries at ₹1,154.20, citing unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their view steady. What's in the News Board meeting scheduled for February 3, 2026, to consider unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).
GLAND
₹1,706.40
Gland Pharma
7D
-8.3%
1Y
4.7%

GLAND: Future Returns Will Be Guided By Margin Strength And Regulatory Approvals

Analysts now place Gland Pharma's price target at ₹1,964, slightly below the prior ₹1,970. The revision reflects updated assumptions around revenue growth, profit margin, and a modestly lower future P/E multiple.
LAURUSLABS
₹1,045.90
Laurus Labs
7D
-4.3%
1Y
80.2%

LAURUSLABS: Steady Fair Value And Solid Fundamentals Will Support Upside

Analysts have kept their price target for Laurus Labs steady at ₹1,280, reflecting small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E. These changes are consistent with recent Street research, where targets shifted within a relatively tight range and analysts cited solid fundamentals alongside mixed near term signals.
500257
₹2,332.40
Lupin
7D
0.4%
1Y
15.5%
ERIS
₹1,370.20
Eris Lifesciences
7D
0.7%
1Y
7.9%

ERIS: Diabetes Partnership Will Drive Future Upside

Analysts have modestly trimmed their price target on Eris Lifesciences from ₹1,778.20 to ₹1,743.60, citing recalibrated expectations for revenue growth and future P/E, along with slightly higher projected profit margins. What's in the News Eris Lifesciences entered a partnership with Natco Pharma for the commercialisation of semaglutide in India, focusing on Type 2 diabetes and chronic weight management therapies (Client Announcements).
ZYDUSLIFE
₹914.65
Zydus Lifesciences
7D
-2.5%
1Y
0.8%
500420
₹4,353.15
Torrent Pharmaceuticals
7D
-1.1%
1Y
42.3%
CIPLA
₹1,326.40
Cipla
7D
-2.3%
1Y
-9.3%

CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook

Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).
ACUTAAS
₹2,234.90
Acutaas Chemicals
7D
2.3%
1Y
81.5%

ACUTAAS: Updated Earnings Outlook And ESOP Plans Will Shape Balanced View

Analysts have nudged their price target on Acutaas Chemicals up from ₹2,084.88 to ₹2,131.00, reflecting updated assumptions on fair value, slightly adjusted expectations for revenue growth and profit margins, and a lower future P/E multiple in their models. What's in the News Acutaas Chemicals raised its earnings guidance for Fiscal Year 2026, with management now expecting revenue growth in a range upwards from 25% to around 30% (Key Developments).
AUROPHARMA
₹1,225.50
Aurobindo Pharma
7D
0.4%
1Y
10.0%

AUROPHARMA: Margin Assumptions And Lower P/E Multiple Will Test Execution

Analysts have nudged their price target for Aurobindo Pharma slightly higher to ₹1,046.76 from ₹1,043.83, citing adjustments to profit margin assumptions and a lower forward P/E multiple in their updated models. Analyst Commentary Even with the modest upward tweak to the price target, some bearish analysts are still flagging risks that could cap upside for Aurobindo Pharma if execution or assumptions do not line up with reality.
MANKIND
₹2,226.40
Mankind Pharma
7D
-2.3%
1Y
-2.1%

MANKIND: Upcoming Results Will Support Further Upside Despite Modest Assumption Cuts

Analysts have trimmed their price target for Mankind Pharma from about ₹2,631 to about ₹2,537. This reflects slightly lower assumptions for revenue growth, profit margins and future P/E multiples, alongside a modestly reduced discount rate.
ALKEM
₹5,550.00
Alkem Laboratories
7D
-3.5%
1Y
16.9%

ALKEM: Long Dated US Settlements And Dermatology Launch Will Support ReRating

Analysts have trimmed their price target for Alkem Laboratories from ₹7,056 to ₹6,913, reflecting updated views on revenue growth, profit margin assumptions and a slightly lower future P/E multiple. What's in the News Alkem and Axsome Therapeutics reached a settlement on patent litigation over SUNOSI, with Alkem receiving a license to sell a generic version in the US starting on or after March 1, 2040 (or September 1, 2040 if pediatric exclusivity is granted), subject to regulatory approvals and customary conditions (Axsome settlement announcement).
NATCOPHARM
₹1,000.80
NATCO Pharma
7D
2.9%
1Y
21.6%

NATCOPHARM: New Subsidiaries And Leadership Changes Will Support Future Upside

Analysts have trimmed their price target on NATCO Pharma slightly, from about ₹1,414.64 to ₹1,378.76. This reflects updated assumptions around revenue contraction, profit margins, and future P/E expectations.
500488
₹27,595.20
Abbott India
7D
4.8%
1Y
-11.0%
524632
₹43.18
Shukra Pharmaceuticals
7D
7.7%
1Y
79.0%
500660
₹2,478.10
GlaxoSmithKline Pharmaceuticals
7D
-5.6%
1Y
-7.9%